Steris Plc 8-K Summary: 2021 Annual General Meeting Results
Business Context and Reporting Period
This Form 8-K reports the results of the 2021 Annual General Meeting of Shareholders held on July 29, 2021. Steris Plc, incorporated in Ireland, is a global provider of infection prevention and patient safety solutions. The filing details shareholder voting outcomes for director elections, auditor ratification, and executive compensation.
Key Financial Metrics
This filing is a current report regarding corporate governance and does not contain financial performance data. Revenue, profit, cash flow, margins, debt, and liquidity metrics are not provided in this document.
Material Changes and Voting Results
Shareholder participation was high, with 75,668,916 shares (88.63% of outstanding shares) present in person or by proxy. All proposals were approved by the shareholders.
- Director Elections: All nine nominees were re-elected to the Board of Directors for one-year terms. Notable voting statistics include:
- Dr. Jacqueline B. Kosecoff received the highest "against" votes (14,774,137) and lowest "for" votes (58,179,041) among the nominees.
- Dr. Nirav R. Shah received the highest "for" votes (72,788,496).
- Auditor Ratification: Shareholders ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the year ending March 31, 2022.
- Statutory Auditor: Shareholders appointed Ernst & Young Chartered Accountants as the statutory auditor under Irish law.
- Executive Compensation: The non-binding advisory proposal to approve named executive officer compensation was approved with 70,427,202 votes for and 2,486,333 votes against.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. It strictly reports the certified voting results of the Annual General Meeting.
Key Facts for Investor Verification
- Verify the re-election of Dr. Jacqueline B. Kosecoff, who received significant dissenting votes compared to other board members.
- Confirm the ratification of Ernst & Young LLP for the fiscal year ending March 31, 2022.
- Note the high level of shareholder engagement, with 88.63% of outstanding shares represented at the meeting.
- Review the proxy statement dated June 14, 2021, for detailed executive compensation data referenced in the advisory vote.